Clonal haematopoiesis of indeterminate potential (CHIP) is defined as an expansion of mutant blood stem cells in individuals without haematological malignancies. CHIP is linked to an increased risk of non-cancerous disorders such as atherosclerotic cardiovascular disease, possibly because mutant innate immune cells have pro-inflammatory phenotypes. Prospective studies are needed to determine whether individuals with CHIP might benefit from anti-inflammatory therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat. Med. 27, 1921–1927 (2021).
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
Lin, A. E., Rauch, P. J., Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis: confluence of malignant and nonmalignant diseases. Annu. Rev. Cancer Biol. 6, 187–200 (2022).
Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017).
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).
Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Svensson, E. C. et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 7, 521–528 (2022).
Sidlow, R. et al. The clinical challenge of clonal hematopoiesis, a newly recognized cardiovascular risk factor. JAMA Cardiol. 5, 958–961 (2020).
Swirski, F. K. From clonal haematopoiesis to the CANTOS trial. Nat. Rev. Cardiol. 15, 79–80 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.J. is a consultant to AVRO Bio, Foresite Labs, Novartis and Roche Genentech; reports speaking fees from GSK; is on the scientific advisory board of Bitterroot Bio; and is a founder, equity holder and on the scientific advisory board of TenSixteen Bio. H.A. declares no competing interests.
Rights and permissions
About this article
Cite this article
Ahmad, H., Jaiswal, S. Clonal haematopoiesis and atherosclerotic cardiovascular disease. Nat Rev Cardiol 20, 437–438 (2023). https://doi.org/10.1038/s41569-023-00882-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-023-00882-2
This article is cited by
-
IL-6R antagonism ameliorates atherosclerosis linked to Tet2-related clonal haematopoiesis
Nature Reviews Cardiology (2023)